104 results
Page 3 of 6
F-3MEF
EX-23.1
vdiyl 748cce
9 Feb 21
Registration statement to add securities to prior F-3 registration
9:40pm
F-3MEF
EX-5.1
ychxg5
9 Feb 21
Registration statement to add securities to prior F-3 registration
9:40pm
F-3MEF
uo8yh hcwbr13fwv
9 Feb 21
Registration statement to add securities to prior F-3 registration
9:40pm
424B5
nxae ntatlwn
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-10.1
k8en18d6thvrsu9 40
22 Oct 20
Report of Foreign Private Issuer
8:47am
424B5
yfd8ptgiegn4qzxlesv
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
y13cap phc87nwxzuo
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-99.1
4lxgse3
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-99.1
xn2s4geva573f4eqc
13 Apr 20
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
8:32am
6-K
EX-4.1
girt3o
5 Mar 20
Report of Foreign Private Issuer
8:16am
6-K
EX-1.1
chimk4884vnjo864
5 Mar 20
Report of Foreign Private Issuer
8:16am
6-K
EX-4.2
wxa5tnkk7c8kai0pw
5 Mar 20
Report of Foreign Private Issuer
8:16am
424B5
jm3mq8
3 Mar 20
Prospectus supplement for primary offering
5:13pm
6-K
EX-1.1
h5moqi
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
6-K
EX-4.1
zvc2vfcf2d51zf9y
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
424B5
ybx0cz nj8g
26 Feb 20
Prospectus supplement for primary offering
8:23am
20-F/A
EX-15.1
ogyyymz6 zlmxg3
23 Jan 20
Annual report (foreign) (amended)
4:31pm